DOI QR코드

DOI QR Code

Effects of Statins on the Epicardial Fat Thickness in Patients with Coronary Artery Stenosis Underwent Percutaneous Coronary Intervention: Comparison of Atorvastatin with Simvastatin/Ezetimibe

  • Park, Jae-Hyeong (Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Park, Yun-Seon (Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Kim, Yeon-Ju (Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Lee, In-Sook (Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Kim, Jun-Hyung (Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Lee, Jae-Hwan (Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Choi, Si-Wan (Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Jeong, Jin-Ok (Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital) ;
  • Seong, In-Whan (Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital)
  • Published : 2010.12.27

Abstract

Background: Epicardial fat is a visceral thoracic fat and known to be related with presence of dyslipidemia and coronary arterial stenosis. We evaluated the effects and differences of statins on epicardial fat thickness (EFT) in patients underwent successful percutaneous coronary intervention (PCI). Methods: In this retrospective cohort study, we enrolled consecutive patients underwent successful PCI and scheduled six to eight-months follow-up coronary angiography from March 2007 to June 2009. EFT was measured by echocardiography twice at the time of PCI and the follow-up coronary angiography. We included 145 patients (58 females; mean, 63.5 ${\pm}$ 9.5 years). Results: Of the 145 patients, 82 received 20 mg of atorvastatin (atorvastatin group) and 63 medicated with 10 mg of simvastatin with 10 mg of ezetimibe (simvastatin/ezetimibe group). With statin treatments, total cholesterol concentration (189.1 ${\pm}$ 36.1 to 143.3 ${\pm}$ 36.5 mg/dL, p < 0.001), triglycerides (143.5 ${\pm}$ 65.5 to 124.9 ${\pm}$ 63.1 mg/dL, p = 0.005), low density lipoprotein-cholesterol (117.4 ${\pm}$ 32.5 to 76.8 ${\pm}$ 30.9 mg/dL, p < 0.001) and EFT (4.08 ${\pm}$ 1.37 to 3.76 ${\pm}$ 1.29 mm, p < 0.001) were significantly decreased. Atorvastatin and simvastatin/ezetimibe showed similar improvements in the cholesterol profiles. However, atorvastatin decreased EFT more significantly than simvastatin/ezetimibe (EFT change 0.47 ${\pm}$ 0.65 in the atorvastatin vs. 0.12 ${\pm}$ 0.52 mm in the simvastatin/ezetimibe group; p = 0.001). Conclusion: In this study, the atorvastatin group showed significant reduction in EFT than in the simvastatin/ezetimibe group. This might be originated from the statin difference. More large, randomized study will be needed to evaluate this statin difference.

Keywords

References

  1. Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J 2007;153:907-17. https://doi.org/10.1016/j.ahj.2007.03.019
  2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288: 2709-16. https://doi.org/10.1001/jama.288.21.2709
  3. Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesityassociated cardiovascular disease. Circulation 2002;105:2923-8. https://doi.org/10.1161/01.CIR.0000017823.53114.4C
  4. Ahn SG, Lim HS, Joe DY, Kang SJ, Choi BJ, Choi SY, Yoon MH, Hwang GS, Tahk SJ, Shin JH. Relationship of epicardial adipose tissue by echocardiography to coronary artery disease. Heart 2008;94:e7. https://doi.org/10.1136/hrt.2007.118471
  5. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003;88: 5163-8. https://doi.org/10.1210/jc.2003-030698
  6. Krysiak R, Labuzek K, Okopien B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep 2009;61:1134-45. https://doi.org/10.1016/S1734-1140(09)70176-8
  7. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1: 307-10.
  8. Ho E, Shimada Y. Formation of the epicardium studied with the scanning electron microscope. Dev Biol 1978;66:579-85. https://doi.org/10.1016/0012-1606(78)90263-4
  9. Taguchi R, Takasu J, Itani Y, Yamamoto R, Yokoyama K, Watanabe S, Masuda Y. Pericardial fat accumulation in men as a risk factor for coronary artery disease. Atherosclerosis 2001;157:203-9. https://doi.org/10.1016/S0021-9150(00)00709-7
  10. Marchington JM, Mattacks CA, Pond CM. Adipose tissue in the mammalian heart and pericardium: structure, foetal development and biochemical properties. Comp Biochem Physiol B 1989;94:225-32.
  11. Marchington JM, Pond CM. Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. Int J Obes 1990; 14:1013-22.
  12. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005;2:536-43. https://doi.org/10.1038/ncpcardio0319
  13. Iacobellis G, Pond CM, Sharma AM. Different "weight" of cardiac and general adiposity in predicting left ventricle morphology. Obesity (Silver Spring) 2006;14:1679-84. https://doi.org/10.1038/oby.2006.192
  14. Iacobellis G, Sharma AM. Adiposity of the heart. Ann Intern Med 2006;145:554-5. https://doi.org/10.7326/0003-4819-145-7-200610030-00021
  15. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 2003;11:304-10. https://doi.org/10.1038/oby.2003.45
  16. Park EM, Choi JH, Shin IS, Yun KH, You NJ, Oh SK, Kim NH, Jeong JW. Echocardiographic epicardial fat thickness on short term prognosis in patients with acute coronary syndrome. J Cardiovasc Ultrasound 2008; 16:42-7. https://doi.org/10.4250/jcu.2008.16.2.42
  17. Iacobellis G, Pellicelli AM, Sharma AM, Grisorio B, Barbarini G, Barbaro G. Relation of subepicardial adipose tissue to carotid intimamedia thickness in patients with human immunodeficiency virus. Am J Cardiol 2007;99:1470-2. https://doi.org/10.1016/j.amjcard.2006.12.082
  18. Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, Rhee SJ, Lee EM, Lee J, Yoo NJ, Kim NH, Park JC. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007;71:536-9. https://doi.org/10.1253/circj.71.536
  19. Okauchi Y, Nishizawa H, Funahashi T, Ogawa T, Noguchi M, Ryo M, Kihara S, Iwahashi H, Yamagata K, Nakamura T, Shimomura I, Matsuzawa Y. Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men. Diabetes Care 2007;30: 2392-4. https://doi.org/10.2337/dc07-0218
  20. Busetto L, Tregnaghi A, Bussolotto M, Sergi G, Benincà P, Ceccon A, Giantin V, Fiore D, Enzi G. Visceral fat loss evaluated by total body magnetic resonance imaging in obese women operated with laparascopic adjustable silicone gastric banding. Int J Obes Relat Metab Disord 2000; 24:60-9. https://doi.org/10.1038/sj.ijo.0801086
  21. Iacobellis G, Sharma AM. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des 2007;13:2180-4. https://doi.org/10.2174/138161207781039670
  22. Iacobellis G, Singh N, Wharton S, Sharma AM. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity (Silver Spring) 2008;16:1693-7. https://doi.org/10.1038/oby.2008.251
  23. Steinberg D. The statins in preventive cardiology. N Engl J Med 2008; 359:1426-7. https://doi.org/10.1056/NEJMp0806479
  24. Ray KK, Cannon CP. The potential relevance of the multiple lipidindependent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005;46:1425-33. https://doi.org/10.1016/j.jacc.2005.05.086
  25. Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S, McTernan PG. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006;5:1. https://doi.org/10.1186/1475-2840-5-1
  26. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81. https://doi.org/10.1016/S0140-6736(00)04053-8
  27. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43. https://doi.org/10.1056/NEJMoa0800742

Cited by

  1. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features vol.22, pp.11, 2010, https://doi.org/10.1016/j.tem.2011.07.003
  2. Epicardial fat: From the biomolecular aspects to the clinical practice vol.43, pp.12, 2011, https://doi.org/10.1016/j.biocel.2011.09.006
  3. Epicardial Fat Thickness in Heart Failure and Other Clinical Conditions vol.64, pp.3, 2010, https://doi.org/10.1177/0003319712450310
  4. Perivascular adipose tissue in the pathogenesis of cardiovascular disease vol.230, pp.2, 2010, https://doi.org/10.1016/j.atherosclerosis.2013.07.037
  5. Evaluation of epicardial adipose tissue in familial partial lipodystrophy vol.7, pp.None, 2010, https://doi.org/10.1186/s13098-015-0024-5
  6. Does Echocardiographic Epicardial Adipose Tissue Thickness become a Useful Biomarker? vol.22, pp.6, 2015, https://doi.org/10.5551/jat.ed015
  7. Local and systemic effects of the multifaceted epicardial adipose tissue depot vol.11, pp.6, 2010, https://doi.org/10.1038/nrendo.2015.58
  8. Epicardial fat thickness regression with continuous positive airway pressure therapy in patients with obstructive sleep apnea: assessment by two-dimensional echocardiography vol.128, pp.5, 2016, https://doi.org/10.1007/s00508-016-0975-z
  9. Relationship between epicardial fat and quantitative coronary artery plaque progression: insights from computer tomography coronary angiography vol.32, pp.2, 2010, https://doi.org/10.1007/s10554-015-0762-3
  10. Epicardial Fat: Physiological, Pathological, and Therapeutic Implications vol.2016, pp.None, 2010, https://doi.org/10.1155/2016/1291537
  11. Epicardial adipose tissue: at the heart of the obesity complications vol.54, pp.9, 2010, https://doi.org/10.1007/s00592-017-1020-z
  12. Adipokines and cardiovascular disease: A comprehensive review vol.161, pp.1, 2010, https://doi.org/10.5507/bp.2017.002
  13. Original research. The Assessment of Epicardial Adipose Tissue in Acute Coronary Syndrome Patients. A Systematic Review vol.3, pp.1, 2017, https://doi.org/10.1515/jce-2017-0003
  14. Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes vol.16, pp.None, 2010, https://doi.org/10.1186/s12933-017-0528-4
  15. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus vol.9, pp.None, 2010, https://doi.org/10.1186/s13098-017-0275-4
  16. Abnormal Peri-Organ or Intra-Organ Fat Deposition and Vascular Risk vol.69, pp.10, 2010, https://doi.org/10.1177/0003319718776528
  17. Cardiac magnetic resonance based evaluation of aortic stiffness and epicardial fat volume in patients with hypertension, diabetes mellitus, and myocardial infarction vol.59, pp.1, 2010, https://doi.org/10.1177/0284185117706201
  18. Impact of Epicardial Adipose Tissue, Left Ventricular Myocardial Fat Content, and Interstitial Fibrosis on Myocardial Contractile Function vol.11, pp.8, 2010, https://doi.org/10.1161/circimaging.117.007372
  19. Atorvastatin and Fenofibrate Exert Opposite Effects on the Vascularization and Characteristics of Visceral Adipose Tissue in New Zealand White Rabbits vol.24, pp.6, 2019, https://doi.org/10.1177/1074248419838517
  20. Tai Chi Improves Coronary Heart Disease Risk by Inactivating MAPK/ERK Pathway through Serum miR-126 vol.2020, pp.None, 2010, https://doi.org/10.1155/2020/4565438
  21. Epicardial Adipose Tissue as a New Target of Therapeutic Interventions vol.16, pp.4, 2010, https://doi.org/10.20996/1819-6446-2020-08-15
  22. Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction-A Specific HFpEF Phenotype vol.8, pp.None, 2021, https://doi.org/10.3389/fcvm.2021.720690
  23. Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes? vol.26, pp.5, 2010, https://doi.org/10.1177/10742484211006997
  24. Epicardial Fat in the Maintenance of Cardiovascular Health vol.13, pp.1, 2010, https://doi.org/10.14797/mdcj-13-1-20